Neuphoria Therapeutics Inc (NEUP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.80M
Last updated: Nov 17, 2026 at 11:04 AM ET
Neuphoria Therapeutics Inc (NEUP) Financials: Revenue, Profit and Cash Flow
Neuphoria Therapeutics reported revenue of $1.17M for the fiscal year ended Jun 30, 2026, down 92.5% from the year before. That year, net income was -$13.45M with a net margin of -1145.7% and operating cash flow was -$12.35M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$505.06K.
Revenue and Margins
Over the 9 years to Jun 2026, revenue fell from $4.13M, a compound annual decline of 13.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $1.17M | -92.5% | 100.0% | -1401.1% | -1145.7% |
| Jun 2025 | $15.65M | N/A | 100.0% | -7.2% | -2.4% |
| Jun 2024 | $0 | N/A | N/A | N/A | N/A |
| Jun 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Jun 2022 | $188.85K | +4266.6% | 100.0% | -9917.0% | -7955.8% |
| Jun 2021 | $4.33K | -86.6% | -53024.6% | -251187.4% | -151078.1% |
| Jun 2020 | $32.27K | -98.8% | -6935.5% | -29821.1% | -15254.9% |
| Jun 2019 | $2.68M | -2.9% | 100.0% | -401.6% | -252.8% |
| Jun 2018 | $2.76M | -33.3% | 100.0% | -771.8% | -668.3% |
| Jun 2017 | $4.13M | N/A | 100.0% | -261.5% | -125.6% |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Mar 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17M | $15.65M | $0 | $0 | $188.85K | $4.33K | $32.27K | $2.68M | $2.76M | $4.13M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $2.30M | $2.27M | $12.13M | $25.25M | $24.22M |
| Gross profit | $1.17M | $15.65M | $0 | $0 | $188.85K | -$2.29M | -$2.24M | $2.68M | $2.76M | $4.13M |
| Research and development | $3.55M | $9.01M | $9.42M | $13.07M | $11.05M | $4.33M | $4.03M | $6.29M | $18.55M | $18.61M |
| Operating income | -$16.45M | -$1.13M | -$17.89M | -$21.98M | -$18.73M | -$10.86M | -$9.62M | -$10.76M | -$21.28M | -$10.80M |
| Net income | -$13.45M | -$369.63K | -$15.49M | -$21.38M | -$15.02M | -$6.53M | -$4.92M | -$6.77M | -$18.43M | -$5.19M |
| EBITDA | -$13.59M | -$341.61K | -$15.14M | -$21.32M | -$15.13M | -$6.67M | -$4.17M | N/A | N/A | -$3.75M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$13.27K | $15.00M | $662.72K | $0 | $0 | $0 | $0 | $0 | -$44.72K |
| Gross profit | $0 | -$165.79K | $0 | -$13.27K | $15.00M | $662.72K | $0 | -$165.69K | $0 | $0 | $0 | $3.58M |
| Operating income | -$1.21M | -$6.08M | -$5.65M | -$5.84M | $11.98M | -$3.70M | -$5.65M | -$5.48M | -$2.39M | -$4.55M | -$5.47M | -$11.04M |
| Net income | -$505.06K | $2.79M | -$9.91M | -$8.88M | $11.26M | -$1.94M | -$9.91M | -$2.69M | -$2.78M | -$4.55M | -$5.47M | -$5.28M |
Balance Sheet
As of Jun 2026, cash and equivalents of $19.87M were 69.2% of total assets of $28.71M, against total liabilities of $4.11M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.71M | $28.59M | $27.65M | $28.56M | $45.10M | $40.77M | $23.68M | $37.58M | $47.80M | $64.61M |
| Current assets | $21.07M | $15.04M | $13.19M | $13.33M | $28.87M | $23.24M | $5.73M | $17.60M | $26.39M | $41.86M |
| Cash and equivalents | $19.87M | $14.21M | $12.61M | $12.10M | $23.18M | $21.41M | $3.15M | $9.79M | $18.31M | $32.95M |
| Total liabilities | $4.11M | $9.59M | $10.16M | $6.55M | $5.80M | $5.01M | $14.97M | $25.18M | $35.34M | $33.52M |
| Short-term debt | N/A | $226.49K | $155.11K | $211.83K | $0 | $0 | $4.09M | $5.92M | $4.29M | $6.53M |
| Shareholder equity | $24.60M | $19.00M | $17.49M | $22.01M | $39.30M | $35.76M | $8.71M | $12.39M | $12.46M | $31.09M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.71M | $34.81M | $36.60M | $27.34M | $43.44M | $30.71M | $36.60M | $27.34M | $27.65M | N/A | $38.86M | $22.92M |
| Total liabilities | $4.11M | $5.39M | $6.90M | $14.83M | $14.57M | $4.72M | $6.90M | $14.83M | $10.16M | -$30.35M | $9.82M | $5.85M |
| Cash and equivalents | $19.87M | $19.44M | $22.17M | $13.65M | $21.59M | $17.04M | $22.17M | $13.65M | $12.61M | N/A | $14.87M | $8.08M |
| Shareholder equity | $24.60M | $29.42M | $29.70M | $12.51M | $28.87M | $26.00M | $29.70M | $12.51M | $17.49M | $30.35M | $29.04M | $17.07M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.35M | $77.23K | -$14.68M | -$14.64M | -$15.21M | -$5.66M | -$2.70M | -$10.91M | -$15.02M | -$1.44M |
| Capital expenditures | N/A | $0 | $0 | N/A | $1.54K | $1.10K | $5.33K | $69.28K | $358.11K | $247.51K |
| Free cash flow | N/A | $77.23K | -$14.68M | N/A | -$15.21M | -$5.66M | -$2.70M | -$10.98M | -$15.38M | -$1.69M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $312.15K | $33.35K | N/A | N/A | N/A |
| Investing cash flow | $0 | $0 | $0 | $0 | $487.92K | -$60.26K | -$134.93K | $138.42K | $59.68K | $953.94K |
| Financing cash flow | $17.92M | $1.53M | $15.11M | $3.86M | $22.71M | $23.71M | -$3.70M | $3.05M | $1.94M | -$2.08M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.21M | -$3.87M | -$6.44M | -$3.79M | -$3.59M | $13.89M | -$3.79M | -$3.01M | -$3.30M | -$3.95M | -$4.43M | N/A |
| Capital expenditures | N/A | $2 | $0 | $2 | $3 | $0 | $3 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | N/A | -$3.87M | -$6.44M | -$3.79M | -$3.59M | $13.89M | -$3.79M | -$3.01M | -$3.30M | -$3.95M | -$4.43M | N/A |
Frequently Asked Questions About NEUP
What is Neuphoria Therapeutics' annual revenue?
Neuphoria Therapeutics reported revenue of $1.17M for the fiscal year ended Jun 30, 2026.
How fast is Neuphoria Therapeutics' revenue growing?
Revenue was down 92.5% for the fiscal year ended Jun 30, 2026 compared with the year before.
Is Neuphoria Therapeutics profitable?
No. Neuphoria Therapeutics reported net income of -$13.45M for the fiscal year ended Jun 30, 2026, with a net margin of -1145.7%.
How much debt does Neuphoria Therapeutics have?
The balance sheet dated Jun 30, 2026 reported cash and equivalents of $19.87M.
What is NEUP's profit margin?
For the fiscal year ended Jun 30, 2026, Neuphoria Therapeutics reported gross margin of 100.0%, operating margin of -1401.1% and net margin of -1145.7%.
NEUP pages: Overview, Earnings, Forecast, Financials, Competitors